Company / EPS (Basic)
ALNYLAM PHARMACEUTICALS, INC. EPS (Basic) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$3.52
FY2025
5-year range
-$9.30 / -$3.52
FY2021-FY2025
Trend
+62.2%
vs FY2024
Sector context
#159 of 208
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s eps (basic) of $-3.52 is lower than 76% of companies in the Health Care sector (FY2025). Improved from $-7.20 to $-3.52 over the past 2 years.
Based on SEC 10-K filings.
-3.52 in FY2025.
Improved from $-7.20 to $-3.52 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 208This company -$3.52 Sector average -$0.96
▼
-265.5% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 62.2% year-over-year.
- Ranks #159 out of 208 companies in the Health Care sector.
- Lowest eps (basic) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.52 | +62.2% |
| FY2024 | -$9.30 | -29.2% |
| FY2023 | -$7.20 | +3.5% |
| FY2022 | -$7.46 | +8.0% |
| FY2021 | -$8.11 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026